The Nasdaq-listed psychedelic medicine developer is expanding its workforce, preparing a US sales operation and engaging healthcare providers ahead of ...
Compass Pathways has reported positive six-month results from its second Phase 3 clinical trial evaluating COMP360 psilocybin treatment for treatment-resistant ...
Compass Pathways has moved closer than any company in the psychedelic medicine sector to securing U.S. regulatory approval for a ...
Psychedelics.media delivers trusted news, intelligence, and insights for the global psychedelic medicine industry.
